VC & Startups/Nov 17 edition/Reporting & analysis
ExitsValuationsVenture data

ExitsIPOs, listings & liquidity

PwC's Mike Bellin calls the 2026 IPO market selective as Anthropic prepares to list at up to $1.4T

PwC's Mike Bellin counts just under 90 traditional U.S. IPOs in 2026, below the 125–175 he considers healthy, while record proceeds lean on a few mega-deals. Investors, he says, discount AI spending lacking a visible path to earnings.

From the Crunchbase News article of November 17, 2026 and cited sources: 2026 has produced a lot of IPO money but few deals. [1] [2]

SOURCES[1] Crunchbase News – PwC's IPO Lead On A Selective Market news.crunchbase.com[2] Renaissance Capital – 2026 IPO Market Stats renaissancecapital.com

AI-assisted, not human-edited. Methodology Corrections Who owns this site

KEY FACTS
What happened
2026 has produced a lot of IPO money but few deals. [1] [2]
Original source
Crunchbase News article, independent perspective
Brief by
AT Pulse research desk AI-assisted; publisher and contact on the desk page
When
November 17, 2026 article published
Evidence
10 sources across 8 sites

Reach: not measured yet

THE CORE IDEAS4 TAKEAWAYS
01

2026 has produced a lot of IPO money but few deals. Bellin's count of about 90 traditional IPOs falls short of his healthy range of 125–175. Meanwhile, Renaissance Capital tallies $149.0B raised so far this year, mostly from SpaceX and SK hynix, even as its deal count is down 35.9% from last year. [1] [2]

02

The third quarter shows how concentrated the market has become. A single listing supplied about 80% of the quarter's $32.8B. The share of IPOs pricing below their marketed range roughly doubled to 30.4%. The median deal was $211M, and the average return from offer price was slightly negative. Data providers' Q3 deal counts and proceeds totals differ. [4] [8]

03

Bellin's test for listing candidates is durable, diversified revenue plus a credible profitability measure such as GAAP earnings, EBITDA or free cash flow. Mid-market companies without strong growth face narrow windows. SPACs are back in use, with 158 SPAC IPOs this year, and pharma acquirers are buying biotechs before they reach an IPO. [1] [2]

04

Anthropic set a range of $70–$78 per share for 825M shares, implying up to about $1.404T fully diluted, while AI stocks were selling off. Its S-1 shows $17B in Q3 revenue against a $104B net loss over nine months. Seven chip and cloud companies committed to a $26B private placement at the IPO price. Pricing is planned for Nov 18. [5] [3] [7] [6]

WHY IT MATTERS

The evidence: deal count fell sharply and Q3 pricing weakened, even as mega-listings set a proceeds record.

Read the full assessment

The implication: AI companies aiming to list in 2027 likely need clear profitability metrics, and Anthropic's reception could set the tone for early-2027 issuance.

Executive brief

In a Crunchbase News Q&A published Nov 17, 2026, PwC's U.S. IPO services leader Mike Bellin said 2026 has produced "just south of 90" traditional IPOs. He puts a healthy year at 125–175, so by his count this one falls short. Dollar proceeds tell a different story: Renaissance Capital counts $149.0B raised year to date, with SpaceX and SK hynix making up most of it. Bellin's description is a "very selective" market. He says investors aren't doubting AI itself. They're doubting AI spending that has no visible path to earnings. Anthropic's roughly $1.4T IPO, set to price on Nov 18, will test that view.

What changed and event timeline

  1. SpaceX lists

    SpaceX went public seeking a valuation of about $1.75T, per. It became one of two mega-deals that dominate 2026 proceeds.

  2. Q3 review shows concentration

    Renaissance's Q3 review, as summarized by, found that one listing supplied about 80% of the quarter's $32.8B. It also found 30.4% of IPOs priced below their marketed range, up from 15.6% in Q2.

  3. Anthropic sets range during a sell-off

    The range is $70–$78 for 825M shares, implying up to $1.404T fully diluted (). The Nasdaq had fallen 5.5% the week before ().

  4. AI stocks slide again

    The Nasdaq fell 2.49%. Nvidia dropped 4.1%, and Micron and Intel each lost more than 7%, per.

  5. PwC outlook published

    Bellin calls the market selective rather than shut. He expects a strong but selective 2027 if momentum builds in late 2026 ().

Capabilities and access

This is a capital-markets story, not a product launch, so there is no model release to describe.

Read the full section

This is a capital-markets story, not a product launch, so there is no model release to describe. Public access to frontier AI equity is the relevant change:

  • Anthropic (ticker "ANT") plans to price on Nov 18 and trade on Nasdaq around Nov 19 (CNBC guide).
  • AMD, Broadcom, Google, Micron, Microsoft, Nvidia and TSMC agreed to a $26B private placement of non-voting Class N shares at the IPO price (TechCrunch).

Technical analysis for researchers and developers

The main analytical problem is how deals are counted: Proceeds-weighted figures hide how thin the market really is. In Q3 the median deal was $211M, and the average return from offer price to Sept 30 was −0.1%.

Read the full section

The main analytical problem is how deals are counted:

  • Bellin's "~90" covers traditional IPOs only.
  • Renaissance's 123 uses its own filters. It excludes SPACs, closed-end funds and unit offerings, per Kadenwood.
  • Q3 counts disagree too. One summary gives 30 listings and $32.8B, with 23 traditional IPOs once direct listings are removed. Another gives 31 listings and $34.9B (search summary of Renaissance).

Proceeds-weighted figures hide how thin the market really is. In Q3 the median deal was $211M, and the average return from offer price to Sept 30 was −0.1%.

Claims and evidence

  • Anthropic's financials come from its S-1, as reported by TechCrunch. The $81B run-rate figure is self-reported and not audited.
  • Prior valuations: $965B in a May private round. A $2T target was reported earlier, but only from unconfirmed reports (TechCrunch; Fortune).
  • Bellin's points on SPACs and biotech are his own view.
Read the full section
  • Anthropic's financials come from its S-1, as reported by TechCrunch. They show Q3 revenue of $17B, a nine-month net loss of $104B and compute commitments of $900.9B. The $81B run-rate figure is self-reported and not audited.
  • Prior valuations: $965B in a May private round. A $2T target was reported earlier, but only from unconfirmed reports (TechCrunch; Fortune).
  • Bellin's points on SPACs and biotech are his own view. PwC sells IPO advisory services, so it has a commercial interest in a busy pipeline.

Context and prior work

Earlier in 2026, Bellin had laid out a constructive IPO outlook (Pipeline Road, Mar 2026). By late summer, coverage described a post-Labor Day window that still looked open (ION Analytics). Proceeds hit a record, but Renaissance still shows deal count down 35.9% from last year. The 2026 pattern is a few mega-listings sitting on top of shrinking breadth.

Limitations, safety and contested findings

  • The Crunchbase account is a summarized Q&A. Bellin's numbers are approximate and are not tied to any dataset.
  • Data providers disagree on Q3 counts and proceeds (see above).
  • Fortune lists several drivers of the AI sell-off: Democratic midterm gains raising regulatory fears, scrutiny of data-center buildout, and a board investigation into Nvidia CEO Jensen Huang (Fortune).
Read the full section
  • The Crunchbase account is a summarized Q&A. Bellin's numbers are approximate and are not tied to any dataset.
  • Data providers disagree on Q3 counts and proceeds (see above).
  • Fortune lists several drivers of the AI sell-off: Democratic midterm gains raising regulatory fears, scrutiny of data-center buildout, and a board investigation into Nvidia CEO Jensen Huang (Fortune). CNBC instead attributes the pressure to Huang's resignation (CNBC). The reviewed sources do not reconcile these accounts.
  • Order-book claims (for example, "six times covered") appear only in secondary outlets and are not confirmed.

Business and practitioner implications

  • IPO-track AI companies: Bellin's bar is durable, diversified revenue plus a credible profitability metric (GAAP, EBITDA or free cash flow).
  • Mid-market companies have limited windows unless they show strong growth. Large issuers can choose their timing (Crunchbase News).
  • Alternatives: SPACs are back in favor because they fix the valuation on day one, and Renaissance counts 158 SPAC IPOs this year.
Read the full section
  • IPO-track AI companies: Bellin's bar is durable, diversified revenue plus a credible profitability metric (GAAP, EBITDA or free cash flow). AI spending without visibility into earnings gets discounted.
  • Mid-market companies have limited windows unless they show strong growth. Large issuers can choose their timing (Crunchbase News).
  • Alternatives: SPACs are back in favor because they fix the valuation on day one, and Renaissance counts 158 SPAC IPOs this year. In biotech, pharma acquisitions are taking companies out before they reach an IPO.
  • Watch item: how Anthropic prices and trades the week of Nov 18–19 will strongly influence early-2027 issuance.
FOLLOW THE EVIDENCE

The source trail.

Sources (10)
A LITTLE LESS NOISE. A LOT MORE CONTEXT.

Stay curious.
Follow the evidence.

Independent perspectives, the original sources, and room for the questions that don't have easy answers.

How we build the brief
Connect with us

Find us where you already read.